Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies

Journal of General Virology

Volumn 81, Issue 1, 2000, Pages 85-95

  Ibáñez, Angela ^a   Clotet, Bonaventura ^a   Martínez, Miguel Angel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; PROTEINASE; VIRUS ENZYME;

ARTICLE; CASE REPORT; ENVELOPE GENE; GENE SEQUENCE; GENETIC DRIFT; GENETIC RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA; VIRUS GENE; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0343049030     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-81-1-85     Document Type: Article

References (52)

1. Blaak, H., Brouwer, M., Ran, L. J., de Wolf, F. & Schuitemaker, H. (1998). In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. Journal of Infectious Diseases 177, 600-610.
2. Boden, D. & Markowitz, M. (1998). Resistance to human immuno-deficiency virus type 1 protease inhibitors. Antimicrobial Agents and Chemotherapy 42, 2775-2783.
3. Boom, R., Sol, C. J. A., Salimans, M. M. M., Jansen, C. L., Wertheim-van Dillen, P. M. E. & van der Noordaa, J. (1990). Rapid and simple method for purification of nucleic acids. Journal of Clinical Microbiology 28, 495-503.
4. Cabana, C., Clotet, B. & Martínez, M.-A. (1999). Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors. Journal of Medical Virology 59, 480-490.
5. Chao, L. (1990). Fitness of RNA virus decreased by Muller's ratchet. Nature 348, 454-455.
6. Cheynier, R., Henrichwark, S., Hadida, F., Pelletier, E., Oksenhendler, E., Autran, B. & Wain-Hobson, S. (1994). HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 78, 373-387.
7. Cheynier, R., Gratton, S., Halloran, M., Stahmer, I., Letvin, N. L. & Wain-Hobson, S. (1998). Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination. Nature Medicine 4, 421-427.
8. Clarke, D. K., Duarte, E. A., Moya, A., Elena, S. F., Domingo, E. & Holland, J. J. (1993). Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses. Journal of Virology 67, 222-228.
9. Cleland, A., Watson, H. G., Robertson, P., Ludlam, C. A. & Leigh-Brown, A. (1996). Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 12, 6-18.
10. Coffin, J. M. (1995). HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489.
11. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K. E., Deutsch, P. J. & Emini, E. A. (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374. 569-571.
12. Condra, J. H., Holder, D. J., Schleif, W. A., Blahy, O. M., Danovich, R. M., Gabryelski, L. J., Graham, D. J., Laird, D., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Yang, T., Chodakewitz, J. A., Deutsch, P. J., Leavitt, R. Y., Massari, F. E., Mellors, J. W., Squires, K. E., Steigbigel, R. T., Teppler, H. & Emini, E. A. (1996). Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. Journal of Virology 70, 8270-8276.
13. Delwart, E. L., Pan, H., Neumann, A. & Markowitz, M. (1998). Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. Journal of Virology 72, 2416-2421.
14. Domingo, E., Escarmís, C., Sevilla, N., Moya, A., Elena, S. F., Quer, J., Novella, I. S. & Holland, J. J. (1996). Basic concepts in RNA virus evolution. FASEB Journal 10, 859-864.
15. Domingo, E., Menendez-Arias, L., Quiñnes-Mateu, M. E., Holguin, A., Gutiérrez-Rivas, M., Martínez, M. A., Quer, J., Novella, I. S. & Holland, J. J. (1997). Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Progress in Drug Research 48, 99-128.
16. Dopazo, J. (1995). Windows Easy Tree software package (version 1.3). http://www.tdi.es/programas/WET-i.html
17. Duarte, E. A., Clarke, D., Moya, A., Domingo, E. & Holland, J. J. (1992). Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet. Proceedings of the National Academy of Sciences, USA 89, 6015-6019.
18. Ercoli, L., Sarmati, L., Nicastri, E., Giannini, G., Galluzzo, C., Vella, S. & Andreoni, M. (1997). HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity. AIDS 11, 1211-1217.
19. Escarmis, C., Dávila, M., Charpentier, N., Bracho, A., Moya, A. & Domingo, E. (1996). Genetic lesions associated with Muller's ratchet in an RNA virus. Journal of Molecular Biology 264, 255-267.
20. Felsenstein, J. (1985). Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39, 783-791.
21. Felsenstein, J. (1988). Phylogenies from molecular sequences : inference and reliability. Annual Review of Genetics 22, 521-565.
22. Felsenstein, J. (1995). Phylogeny inference package (PHYLIP), version 3.57c. University of Washington, Seattle, WA, USA. http://evolution. genetics.washington.edu/phylip.html
23. Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., Emini, E. A. & Chodakewitz, J. (1997). Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337, 734-739.
24. Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Jr, Feinberg, J. E., Balfour, H. H., Jr, Deyton, L. R., Chodakewitz, J. A. & Fischl, M. A. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 337, 725-733.
25. Havlir, D. V., Eastman, S., Gamst, A. & Richman, D.D. (1996). Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. Journal of Virology 70, 7894-7899.
26. Hirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., BrunVezinet, F., Clotet, B., Demeter, L. M., Hammer, S. M., Jacobsen, D. M., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Vella, S. & Richman, D. D. (1998). Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. Journal of the American Medical Association 279, 1984-1991.
27. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
28. Lech, W. J., Wang, G., Yang, Y. L., Chee, Y., Dorman, K., McCrae, D., Lazzeroni, L. C., Erickson, J. W., Sinsheimer, J. S. & Kaplan, A. H. (1996). In vivo sequence diversity of the protease of human immuno-deficiency virus type 1 : presence of protease inhibitor-resistant variants in untreated subjects. Journal of Virology 70, 2038-2043.
29. Leigh-Brown, A. (1997). Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population Proceedings of the National Academy of Sciences, USA 94, 1862-1865.
30. Leigh-Brown, A. &Cleland, A. (1996). Independent evolution of the env and pol genes of HIV-I during zidovudine therapy. AIDS 10, 1067-1073.
31. Leigh-Brown, A. & Richman, D. D. (1997). HIV-1: gambling on the evolution of drug resistance? Nature Medicine 3, 268-271.
32. Liu, S. L., Schacker, T., Musey, L., Shriner, D., McElrath, M. J., Corey, L. & Mullins, J. I. (1997). Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. Journal of Virology 71, 4284-4295.
33. Lukashov, V. V., Kuiken, C. L. & Goudsmit, J. (1995). Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. Journal of Virology 69, 6911-6916.
34. Mansky, L. M. & Temin, H. M. (1995). Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. Journal of Virology 69, 5087-5094.
35. Martínez, M. A., Cabana, M., Ibáñez, A., Clotet, B., Arnó, A. & Ruiz, L. (1999). Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 256, 180-187.
36. Martínez-Picado, J., Savara, A. V., Sutton, L. & D'Aquila, R. T. (1999). Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. Journal of Virology 73, 3744-3752.
37. Myers, G., Foley, B., Mellors, J. W., Korber, B., Jeang, K. T. & Wain-Hobson, S. (1996). Human retroviruses and AIDS database 1996. Los Alamos, NM : Theoretical Biology, Los Alamos National Laboratory.
38. Nájera, I., Holguin, A., Quiñones-Mateu, M. E., Muñoz-Fernandez, M. A., Nájera, R., López-Galindez, C. & Domingo, E. (1995). Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology 69, 23-31.
39. Nijhuis, M., Schurman, R., Jong, D. D., Schipper, P., Danner, S. & Boucher, C. (1997). Selection of HIV-1 variants with increase fitness during ritonavir therapy. In Program and Abstracts of the 1st International Workshop on HIV Drug Resistances and Treatment Strategies. St Petersburg, USA. June 1997.
40. Nijhuis, M., Boucher, C. A., Schipper, P., Leitner, T., Schuurman, R. & Albert, J. (1998). Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proceedings of the National Academy of Sciences, USA 95, 14441-14446.
41. Novella, I. S., Elena, S. F., Moya, A., Domingo, E. & Holland, J. J. (1995). Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. Journal of Virology 69, 2869-2872.
42. Page, R. D. M. (1996). TreeView : an application to display phylogenetic trees on personal computers. Computer Applications in the Biosciences 12, 357-358.
43. Plikat, U., Nieselt-Struwe, K. & Meyerhans, A. (1997). Genetic drift can dominate short-term human immunodeficiency virus type 1 nef quasispecies evolution in vivo. Journal of Virology 71, 4233-4240.
44. Richman, D. D. (1996). Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Advances in Experimental Medicine and Biology 394, 383-395.
45. Ruiz, L., Nijhuis, M., Boucher, C., Puig, T., Bonjoch, A., Martínez-Picado, J., Marfil, S., de Jong, D., Burger, D., Arnó, A., Balagué, M. & Clotet, B. (1998). Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 19, 19-28.
46. Sanchez-Palomino, S., Rojas, J. M., Martínez, M. A., Fenyö, E. M., Nájera, R., Domingo, E. & Lopez-Galíndez, C. (1993). Dilute passage promotes expression of genetic and phenotypic variants of human immunodeficiency virus type 1 in cell culture. Journal of Virology 67, 2938-2943.
47. Sanchez-Palomino, S., Olivares, I., Yuste, E., Richman, D. D. & Lopez-Galíndez, C. (1996). Random important alterations in HIV-1 viral quasispecies after antiviral treatment. Antiviral Therapy 4, 225-236.
48. Shafer, R. W., Winters, M. A., Palmer, S. & Merigan, T. C. (1998). Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Annals of Internal Medicine 128, 906-911.
49. Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Research 22, 4673-4680.
50. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S. & Shaw, G. M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
51. Wolinsky, S. M., Korber, B. T. M., Neumann, A. U., Daniels, M., Kunstman, K. J., Whetsell, A. J., Furtado, M. R., Cao, Y., Ho, D. D., Safrit, J. T. & Koup, R. A. (1996). Adaptative evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272, 537-542.
52. Yuste, E., Sanchez-Palomino, S., Casado, C., Domingo, E. & López-Galíndez, C. (1999). Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. Journal of Virology 73, 2745-2751.